Laser Vision Correction (LVC) is an elective, self-pay and safe surgical procedure to correct myopia and hyperopia. Since FDA approval 25 years ago, there have been a progression of technological improvements leading to better outcomes and LVC is now one of the safest surgical procedures. With a potential pool of 50 million patients, 6000 trained ophthalmic surgeons regularly treating in over 1000 centers of which 65% are physician owned. Treatments remain low from an earlier peak of 1.4 million to less than 800,000 over last 10 years. The factors preventing patients undergoing surgery have not changed and include the cost of $2000 ± $1000 per eye and fear of laser surgery on their eyes. The latter is overcome by word of mouth referrals and positive social media messaging. In addition, press misinformation and lack of optometrists participating in co-management have not helped grow LVC procedures despite the positive results of the FDA's Patient Reported Outcomes with LASIK studies known as PROWL. The surgery is quick, and patients can be "in and out" in less than two hours with a rapid recovery, minimal postoperative restrictions and within 24 hours have 20/20 vision. Volume and price drives center and physician profitability with a scheduling capacity of two to four patients' treatments per hour. Laser vision correction and especially LASIK, remains the treatment of choice for myopic and hyperopic patients wanting to remove their dependency on glasses and contact lenses.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982707 | PMC |
http://dx.doi.org/10.2147/OPTH.S299752 | DOI Listing |
Sci Rep
December 2024
Clinical Laboratory, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Endophthalmitis is a serious infectious eye disease that causes permanent vision loss. This study developed a method for rapid identification and drug resistance analysis of pathogens in vitreous humor. After short-term rapid culture, 30 Staphylococcus aureus isolates were enriched and purified from the vitreous humor using Fc-MBL@FeO, and then identified by MALDI-TOF MS.
View Article and Find Full Text PDFBiomimetics (Basel)
December 2024
Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada.
Three-dimensional bioprinting (3DP) is transforming the field of regenerative medicine by enabling the precise fabrication of complex tissues, including the retina, a highly specialized and anatomically complex tissue. This review provides an overview of 3DP's principles, its multi-step process, and various bioprinting techniques, such as extrusion-, droplet-, and laser-based methods. Within the scope of biomimicry and biomimetics, emphasis is placed on how 3DP potentially enables the recreation of the retina's natural cellular environment, structural complexity, and biomechanical properties.
View Article and Find Full Text PDFClin Ophthalmol
December 2024
Alcon Vision LLC, Fort Worth, TX, USA.
Purpose: To compare the refractive prediction accuracy of the Optiwave Refractive Analysis (ORA) SYSTEM with the Barrett True-K (BTK) formula in calculating intraocular lens (IOL) power in eyes that underwent cataract surgery after previous myopic photorefractive keratectomy (PRK) or laser-assisted in situ keratomileusis (LASIK).
Methods: This retrospective study evaluated patients aged ≥22 years with prior myopic PRK or LASIK who underwent unilateral or bilateral cataract removal and monofocal IOL implantation using the ORA SYSTEM at 177 sites in the United States. Two datasets were analyzed: All Eyes (ie, all eligible eyes) and First Surgery Eyes (ie, each patient's first implanted eye).
Acta Ophthalmol
December 2024
Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China.
Purpose: To evaluate the long-term effects of implantable collamer lens (ICL) V4c on the biomechanical and morphological properties of crystalline lenses in Chinese adults with high myopia using Brillouin microscopy (BM).
Methods: In this case-control study, 102 highly myopic eyes from 102 patients (18-48 years, preoperative spherical equivalent (SE): -6.00--21.
Retin Cases Brief Rep
May 2024
Retina Vitreous Consultants.
Purpose: To demonstrate the response of a juxtapapillary retinal hemangioblastoma (JRH) to belzutifan in a patient with Von-Hippel-Lindau syndrome (VHL).
Methods: This case report includes fundus photography and optical coherence tomography to compare a juxtapapillary retinal hemangioblastoma (JRH) before and 24 months after treatment with belzutifan.
Results: An 18-year-old woman with VHL was diagnosed with a juxtapapillary retinal hemangioblastoma (JRH) at age 13.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!